Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration
Wassim Abida(Memorial Sloan Kettering Cancer Center), Cora N. Sternberg(Cornell University), Ray McDermott(St. Vincent's University Hospital), Éric Voog(Centre Jean Bernard), Karim Fizazi(Université de Lille), Charles J. Ryan(University of Minnesota), Axel S. Merseburger(Universitäres Kinderwunschzentrum Lübeck), Josep M. Piulats(Institut Català d'Ornitologia), Tony Golsorkhi(Clovis Oncology (United States)), Alan H. Bryce(Mayo Clinic Hospital), Andrea Loehr(Clovis Oncology (United States)), Axel Heidenreich(Centrum für Integrierte Onkologie), Gedske Daugaard(Copenhagen University Hospital), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Akash Patnaik(Johannes Gutenberg University Mainz), Darrin Despain(Clovis Oncology (United States)), Brieuc Sautois(Centre Hospitalier Universitaire de Liège), Simon P. Watkins, Richard Bambury(Cork University Hospital), Jingsong Zhang(Moffitt Cancer Center), Jeremy Shapiro(Cabrini Hospital), David Campbell(Barwon Health), Laurence E. Krieger(Unknown), Andrew D. Simmons(Clovis Oncology (United States)), Simon Chowdhury(Sarah Cannon Research Institute), Celestia S. Higano(University of British Columbia), Melanie Dowson(Clovis Oncology (United Kingdom))
Cited by 676
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k